HK inno.N K-CAB(tegoprazan)美国非糜烂性反流病(NERD)III期达主要终点，将在ACG 2026公布

HK inno.N's K-CAB Meets Primary Endpoints in U.S. Phase 3 Trial - Seoul Economic Daily
Skip to main content
Seoul Economic Daily
Seoul Economic Daily
KST
Seoul Economic Daily
Korea's Leading Business News Since 1960
한국어
Menu
Saved Articles
Newsletters
AI KEY
Settings
|
Summary
|
Save
A
A
A
HK inno.N's K-CAB product line, a novel treatment for gastroesophageal reflux disease. In a Phase 3 trial involving 783 adult patients in the U.S., K-CAB demonstrated efficacy in improving heartburn and acid reflux symptoms. Photo courtesy of HK inno.N
HK inno.N's (195940.KS) gastroesophageal reflux disease drug K-CAB improved heartburn and acid reflux symptoms in a late-stage U.S. trial, raising expectations for its entry into the American market as a new drug application sits with the U.S. Food and Drug Administration.
HK inno.N said on the 12th that its U.S. partner, Sebela Pharmaceuticals, will present Phase 3 results for K-CAB (tegoprazan) in non-erosive reflux disease at the American College of Gastroenterology annual meeting (ACG 2026), which opens on the 14th in Tennessee.
Non-erosive reflux disease involves heartburn and regurgitation caused by stomach acid flowing back into the esophagus, without visible damage to the esophageal lining on endoscopy.
The trial enrolled 783 adult patients in the United States. Participants received either 50 milligrams or 100 milligrams of K-CAB, or a placebo, once daily for four weeks, and symptom improvement was compared across the groups.
Both doses met the primary endpoints. The share of days free of heartburn throughout the day over the four-week period was 17.3% in the placebo group, compared with 26.2% for the 50-milligram group and 30.1% for the 100-milligram group.
The share of nights free of heartburn was also higher for K-CAB, at 36.1% for the 50-milligram dose and 39.9% for the 100-milligram dose, against 27.0% for placebo. Acid reflux symptoms improved as well, and the treatment effect was maintained through a 20-week extension study.
At the same meeting, a further analysis of Phase 3 results for K-CAB in erosive esophagitis is set to receive the American College of Gastroenterology's presidential award. Erosive esophagitis is a condition in which acid reflux causes actual damage to the esophageal lining.
In that analysis, among patients classified as having confirmed gastroesophageal reflux disease, the esophagitis healing rate at week two was 75.4% for K-CAB and 60.7% for lansoprazole, an existing treatment. In a subgroup with milder esophageal damage, however, no statistically significant difference was found between the two drugs.
K-CAB, developed by HK inno.N, is South Korea's 30th domestically developed new drug and belongs to the P-CAB, or potassium-competitive acid blocker, class of acid-suppressing treatments. Since its domestic launch in 2019, it has recorded cumulative outpatient prescriptions of 1.0433 trillion won (about $730 million) through the first half of this year.
The company has signed licensing or finished-product export deals covering 55 countries and has won approval in 24 countries, including South Korea. Sebela filed the new drug application with the FDA in January.
"It is significant that we confirmed K-CAB's clinical value in a large U.S. patient population," an HK inno.N official said. "We will work with our partner to strengthen K-CAB's position in the U.S. market."
#
HKinnoN
#
KCAB
#
tegoprazan
#
GERD
#
FDA
#
PCAB
#
ACG2026
Original reporting by
Park Hong-yong
for Seoul Economic Daily.
AI-translated from Korean. Quotes from foreign sources are based on Korean-language reports and may not reflect exact original wording.
View Korean original
↗
Translation Policy
Watch · Seoul Economic Daily
More →
2:43
After the Fed's Rate Hike, Rethink Your Stock Portfolio
2:43
Most Read This Week
1
-
5
‹
›
1
Military Exemption Boasts Spark Push to Overhaul Athlete Rules
2
Eurozone Rules Out Rescue as France Debt Fears Spread
3
Samsung Quarterly Operating Profit Tops 107 Trillion Won, Beating Nvidia
4
AMRO Lifts Korea's 2026 Growth Forecast Again to 3.3%
5
China's TCL Passes Samsung in LCD TVs, Leads by 0.1 Point
← Back to Home
AI KEY
Preview
↗
Korean Corporate Intelligence Hub
KOSPI · KOSDAQ · 12 sectors
A live, cap-weighted view of every KOSPI and KOSDAQ sector, with same-day Korean reporting distilled by company — built for foreign investors, correspondents and analysts who need to scan Korea before the next session.
Click to explore AI KEY
→
Open AI KEY in full screen
↗
Korea Company Atlas
Preview
↗
Market Ontology · The Feedback Loop
KFTC 2025 · 92 groups · 121,954 articles
An English ontology of the Korean market — how companies, the media, the government and the National Assembly move each other in a loop. Korea's named controlling persons and designated business groups are a mechanism, not a risk to be priced blind.
Click to explore the atlas
→
Open Atlas in full screen
↗
SIGNAL
Now live
↗
English Edition · Capital Markets
M&A · IPO · PE · Fund Flows
SIGNAL English Edition is live — Korea's deal desk reporting in English. M&A, IPOs, private equity and fund flows, covered daily for global institutional investors. Browse free; subscriber-only scoops at the 50% intro rate.
Click to explore SIGNAL
→
Open SIGNAL in full screen
↗